Search by Drug Name or NDC
NDC 00006-3061-00 EMEND 150 mg/5mL Details
EMEND 150 mg/5mL
EMEND is a INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Merck Sharp & Dohme LLC. The primary component is FOSAPREPITANT DIMEGLUMINE.
MedlinePlus Drug Summary
Aprepitant injection and fosaprepitant injection are used along with other medications to prevent nausea and vomiting in adults that may occur within 24 hours or several days after receiving certain cancer chemotherapy treatments. Fosaprepitant injection can also be used in children 6 months of age and older. Aprepitant and fosaprepitant injections are not used to treat nausea and vomiting that you already have. Aprepitant and fosaprepitant injections are in a class of medications called antiemetics. They work by blocking the action of neurokinin, a natural substance in the brain that causes nausea and vomiting.
Related Packages: 00006-3061-00Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Aprepitant/Fosaprepitant Injection
Product Information
| NDC | 00006-3061 |
|---|---|
| Product ID | 0006-3061_18eb4ec1-255e-4861-8dfd-747c0a982b49 |
| Associated GPIs | 50280035102130 |
| GCN Sequence Number | 066837 |
| GCN Sequence Number Description | fosaprepitant dimeglumine VIAL 150 MG INTRAVEN |
| HIC3 | H6J |
| HIC3 Description | ANTIEMETIC/ANTIVERTIGO AGENTS |
| GCN | 29247 |
| HICL Sequence Number | 035346 |
| HICL Sequence Number Description | FOSAPREPITANT DIMEGLUMINE |
| Brand/Generic | Brand |
| Proprietary Name | EMEND |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | FOSAPREPITANT DIMEGLUMINE |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 150 |
| Active Ingredient Units | mg/5mL |
| Substance Name | FOSAPREPITANT DIMEGLUMINE |
| Labeler Name | Merck Sharp & Dohme LLC |
| Pharmaceutical Class | Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Neurokinin 1 Antagonists [MoA], Substance P/Neurokinin-1 Receptor Antagonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA022023 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 00006-3061-00 (00006306100)
| NDC Package Code | 0006-3061-00 |
|---|---|
| Billing NDC | 00006306100 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (0006-3061-00) / 5 mL in 1 VIAL, SINGLE-DOSE (0006-3061-01) |
| Marketing Start Date | 2017-02-03 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |